Cargando…
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by hig...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217155/ https://www.ncbi.nlm.nih.gov/pubmed/37238199 http://dx.doi.org/10.3390/diagnostics13101715 |
_version_ | 1785048469004615680 |
---|---|
author | Zanatta, Elisabetta Martini, Andrea Depascale, Roberto Gamba, Anna Tonello, Marta Gatto, Mariele Giraudo, Chiara Balestro, Elisabetta Doria, Andrea Iaccarino, Luca |
author_facet | Zanatta, Elisabetta Martini, Andrea Depascale, Roberto Gamba, Anna Tonello, Marta Gatto, Mariele Giraudo, Chiara Balestro, Elisabetta Doria, Andrea Iaccarino, Luca |
author_sort | Zanatta, Elisabetta |
collection | PubMed |
description | Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. Results. ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7–399.07] vs. 48.4 [29.9–147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8–520.5] vs. 162 [75.4–255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002–1.011], p = 0.005). Conclusions. Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD. |
format | Online Article Text |
id | pubmed-10217155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102171552023-05-27 CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies Zanatta, Elisabetta Martini, Andrea Depascale, Roberto Gamba, Anna Tonello, Marta Gatto, Mariele Giraudo, Chiara Balestro, Elisabetta Doria, Andrea Iaccarino, Luca Diagnostics (Basel) Article Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. Results. ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7–399.07] vs. 48.4 [29.9–147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8–520.5] vs. 162 [75.4–255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002–1.011], p = 0.005). Conclusions. Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD. MDPI 2023-05-12 /pmc/articles/PMC10217155/ /pubmed/37238199 http://dx.doi.org/10.3390/diagnostics13101715 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zanatta, Elisabetta Martini, Andrea Depascale, Roberto Gamba, Anna Tonello, Marta Gatto, Mariele Giraudo, Chiara Balestro, Elisabetta Doria, Andrea Iaccarino, Luca CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies |
title | CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies |
title_full | CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies |
title_fullStr | CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies |
title_full_unstemmed | CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies |
title_short | CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies |
title_sort | ccl18 as a biomarker of interstitial lung disease (ild) and progressive fibrosing ild in patients with idiopathic inflammatory myopathies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217155/ https://www.ncbi.nlm.nih.gov/pubmed/37238199 http://dx.doi.org/10.3390/diagnostics13101715 |
work_keys_str_mv | AT zanattaelisabetta ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT martiniandrea ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT depascaleroberto ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT gambaanna ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT tonellomarta ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT gattomariele ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT giraudochiara ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT balestroelisabetta ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT doriaandrea ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies AT iaccarinoluca ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies |